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T  lymphocytes, from their first encounter with their specific antigen as naïve cell until 
the last stages of their differentiation, in a replicative state of senescence, go through a 
series of phases. In several of these stages, T lymphocytes are subjected to exponential 
growth in successive encounters with the same antigen. This entire process occurs 
throughout the life of a human individual and, earlier, in patients with chronic infections/
pathologies through inflammatory mediators, first acutely and later in a chronic form. This 
process plays a fundamental role in amplifying the activating signals on T lymphocytes 
and directing their clonal proliferation. The mechanisms that control cell growth are high 
levels of telomerase activity and maintenance of telomeric length that are far superior to 
other cell types, as well as metabolic adaptation and redox control. Large numbers of 
highly differentiated memory cells are accumulated in the immunological niches where 
they will contribute in a significant way to increase the levels of inflammatory mediators 
that will perpetuate the new state at the systemic level. These levels of inflammation 
greatly influence the process of T  lymphocyte differentiation from naïve T  lymphocyte, 
even before, until the arrival of exhaustion or cell death. The changes observed during 
lymphocyte differentiation are correlated with changes in cellular metabolism and these 
in turn are influenced by the inflammatory state of the environment where the cell is 
located. Reactive oxygen species (ROS) exert a dual action in the population of T lym-
phocytes. Exposure to high levels of ROS decreases the capacity of activation and 
T  lymphocyte proliferation; however, intermediate levels of oxidation are necessary for 
the lymphocyte activation, differentiation, and effector functions. In conclusion, we can 
affirm that the inflammatory levels in the environment greatly influence the differentiation 
and activity of T lymphocyte populations. However, little is known about the mechanisms 
involved in these processes. The elucidation of these mechanisms would be of great 
help in the advance of improvements in pathologies with a large inflammatory base such 
as rheumatoid arthritis, intestinal inflammatory diseases, several infectious diseases and 
even, cancerous processes.
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FiGURe 1 | Acute inflammation vs. chronic inflammation. (A) The onset of acute inflammation is characterized by the accumulation of polymorphonuclear 
neutrophils (PMNs) and monocytes that rapidly convert into tissue macrophages, as well as the appearance of edema due to damage in the inflamed tissues. 
Damage-associated molecular patterns and pathogen-associated molecular patterns are recognized by pattern recognition receptors (PRRs) and attract PMNs  
to the place of infection. PMNs represent the first line of defense in infected tissues as they eliminate much of the pathogens or harmful materials by phagocytosis. 
When inflammation occurs, neutrophils suffer apoptosis and they are ingested by macrophages that migrate to the lymph nodes where they will present the 
antigens. (B) Activated T lymphocytes produce cytokines (TNF, IL-17, chemokines) that recruit macrophages and others (IFN-γ) which activate them. T lymphocyte 
subpopulations (Th1, Th2, Th17, etc.) produce diverse types of cytokines and, in turn, activated macrophages and stimulate T lymphocytes via the presentation  
of antigens and through different cytokines (IL-12, IL-6, IL-23). These macrophages also act on neutrophils by releasing molecules, such as TNF and IL-1.
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iNTRODUCTiON
Inflammation is the process in which leukocytes and plasma pro-
teins are recruited from blood into tissues, accumulated and then 
activated to elicit an adequate immune response. Inflammation 
is triggered by recognition of pathogen-associated molecular 
patterns and damage-associated molecular patterns from injured 
tissues during innate immune responses and it is refined and 
prolonged during adaptive immune responses. Many of these 
reactions involve cytokines which are produced by dendritic cells, 
macrophages, and other types of cells during innate immune 
reactions. The leukocytes that are mainly recruited in inflamma-
tion are neutrophils, and monocytes (Figure 1A).
Inflammation can be sensed in the nearby lymph nodes and 
thus influence recruitment and activation of lymphocytes in the 
nodes. Peripheral tissue inflammation, which usually accompa-
nies infections, causes a significant increase of blood flow into 
lymph nodes and consequently an increase in T  lymphocyte 
influx into lymph nodes draining at the site of inflammation. 
T lymphocytes are fully activated only when a foreign peptide is 
recognized in the context of the innate immune system activa-
tion by a pathogen or by some other causes of inflammation. 
In this pro-inflammatory environment, co-stimulatory ligands 
and increase in the expression MHC class I and II molecules are 
induced in antigen-presenting cells (APCs), which are necessary 
for an optimal T lymphocyte activation to occur. There are also 
many inflammatory mediators and cytokines that attract T lym-
phocytes, activating them through their antigenic receptors (1).
Although innate immune stimuli may contribute to chronic 
inflammation, the adaptive immune system may also be involved 
because T lymphocyte-producing cytokines are powerful induc-
ers of inflammation. In this scenario, macrophages are activated 
by type 1 helper T  lymphocytes (Th1  cells), both through cell 
contact and through IFN-γ secretion (2).
When cells that responded to the inflammatory environment 
cannot eliminate pathogens, the acute inflammatory condition 
can become a chronic condition (Figure  1B). In addition to a 
local or systemic inflammatory status, this chronic phase is 
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characterized by a maintained leukocyte infiltrate within the 
injured tissues. This low-grade inflammation is prevalent dur-
ing aging and it is, therefore, denominated as “inflammaging.” 
Furthermore, this phenomenon can also be observed in chronic 
infections, autoimmunity diseases, other chronic inflammatory 
pathologies or cancer. Consequently, all of them are characterized 
by persistent antigens that induce a sustained inflammation con-
comitant with a marked differentiation of the adaptive immunity, 
mainly in T lymphocytes. These highly differentiated cells in turn 
contribute to perpetuate the process by producing increased levels 
of proinflamatory cytokines. During the last stages of differentia-
tion, the pro-inflammatory environment may be responsible for 
an inefficient response of T lymphocytes, as it is shown in older 
individuals (3). Indeed, it has been demonstrated that a reduced 
cytokine-related JAK–STAT signaling is correlated with chronic 
inflammation and age-associated morbidities (4).
T lymphocytes are produced in the bone marrow from where 
they migrate to the thymus for completing the maturation pro-
cess. Then, naïve T lymphocytes recirculate between blood and 
secondary lymphoid organs until they contact their specific anti-
gen adequately and properly. Upon contact, they proliferate and 
acquire properties to assemble an appropriate immune response. 
After antigen elimination, part of these cells remains as memory 
cells, with its own homeostasis and proliferation, though most 
of the effective cells die. Memory cells display a series of migra-
tory and functional features that allow them to mount a quick 
response after the reencounter with the antigen. Therefore, the 
adaptive immune response presents two main advantages for the 
individual. On the one hand, it allows to create a specific immune 
response against the invading pathogen, with which it will finish 
it in a very effective way. On the other hand, a set of memory 
cells is formed to endure for many years thus affording protection 
from new reinfection by the same pathogen.
T  lymphocytes can be categorized using a combination of 
different surface markers (CD45RA, CCR7) in distinct groups 
depending on their functionality. These categories are the naïve 
(CD45RA+CCR7+), effector memory (EM, CD45RA−CCR7−), 
central memory (CM, CD45RA−CCR7+), and effector memory 
RA (EMRA, CD45RA+CCR7−) populations (5). The effector 
T  lymphocytes are a quite heterogeneous population and the 
use of two markers (CD27 and CD28) allows categorizing this 
population into other subpopulations; (CD28−CD27−) is the 
population more differentiated of all (6).
The step from naïve T lymphocytes to effector and memory 
T lymphocytes is one of the most fundamental processes in the 
T  lymphocyte-mediated immunity and requires proliferative, 
metabolic, and oxidative adaptations.
T LYMPHOCYTe PROLiFeRATiON
Naïve T Lymphocyte Homeostasis
The number of naïve T  lymphocytes remains stable in number 
and diversity along the time, when there are no involved power-
ful immune responses. However, T  lymphocytes are neither a 
lethargic nor an immovable cellular population and indeed this 
naïve T lymphocyte pool is continuously interacting with other 
cells through homeostatic signs. The number of T lymphocytes in 
the periphery is almost constant although many new naïve cells 
appear every day from the thymus, especially during the early 
ages of the individual. Therefore, this homeostasis requires a strict 
control as it is very important to maintain this constant number 
along the time. Furthermore, the half-life of naïve T lymphocytes, 
roughly over 50 days, is quite longer than that of other cellular 
populations (7–9). Survival of naïve T  lymphocytes requires 
signals mediated by the interaction of T  lymphocyte receptor 
(TCR)–peptide–MHC and some cytokines, principally IL-7. This 
cytokine is particularly important for the correct T lymphocyte 
homeostasis but its concentration is very low. Thus, all the naïve 
T  lymphocytes including the recent thymic emigrants (RTEs) 
compete for IL-7. If these cells do not receive enough IL-7 signal, 
they would die (Figure 2A). The necessity of soluble mediators 
to intervene in the homeostasis of naïve T lymphocytes has been 
evidenced by the capacity of various cytokines to avoid apoptosis 
of naïve T  lymphocytes. Among these cytokines are IL-4, IL-6, 
lymphopoietin, and IL-7 (10–12), the latter being the one which 
plays a main role (13–15). Supporting this, when an IL-7 blocking 
antibody is injected or naïve cells are transfer into IL-7-deficient 
mice, survival of this subset is greatly diminished (13, 16–18). 
It is also believed that IL-7 is a limiting factor for determining 
the final size of the total lymphocyte pool, as it has been verified 
in several experiments in which the number of lymphocytes 
significantly increases in IL-7-overexpressing mice (19, 20). 
RTEs express low levels of IL-7 receptors, but they are more 
responsive to the cytokine than mature naïve T  lymphocytes. 
Mechanistically, it has been demonstrated that IL-7 signaling in 
RTEs preferentially upregulates the antiapoptotic protein Bcl-2 
expression, resulting in a decrease in cell apoptosis, but without 
an increase in proliferative effects. In contrast, mature naïve cells 
show a decrease in Bcl-2 expression. However, mature naïve cells 
have a greater proliferative response in the presence of IL-7 (21).
During lymphocyte development in the thymus, thymocytes 
reacting to self-molecules are eliminated or believed to be 
induced to produce regulatory T lymphocytes. But, on the other 
hand, in order to overcome positive selection, thymocytes must 
be able to recognize low affinity self-peptide–MHC so they can 
in turn leave the thymus as naïve mature cells (22). This reactiv-
ity to self-peptide–MHC is decreased after positive selection 
(23, 24), but does not disappear in naïve T lymphocytes, since the 
TCR ζ-chain continues to be phosphorylated and this can only 
occur if the TCR meets self-peptide–MHC complexes (25, 26). 
Therefore, consistent data from multiple studies confirm that 
self-peptide–MHC complex interactions are important for long-
term naive T  lymphocyte survival; however, these interactions 
raise much discussion and controversy. Even though there is a 
wide knowledge about the interaction between IL-7R and TCR 
in the homeostasis of naïve T lymphocytes, interestingly many of 
the routes that define the interactions between them are not well 
defined, but it is clear that it must include a mutual regulation 
between these two routes. This is a particularly interesting topic 
and should receive attention in further studies.
There are several works focused on the effect of acute inflam-
mation, for example after bacterial sepsis, in the population of 
naive T lymphocytes. Most of these studies state that the function 
FiGURe 2 | Functional phases of T lymphocytes. Schematic representation of the key factors for survival and maintenance of naïve cells (A) and memory (C); while 
naïve cells are dependent on IL-7 and the contact with self-peptides by MHC, memory cells are dependent on IL-7 and IL-15 and do not need the contact with 
autoantigens. (B) After contact with its specific antigen, naïve T lymphocytes proliferate exponentially and give rise to two differentiated populations, effector 
T lymphocytes and memory T lymphocytes. Effector cells will be eliminated as soon as the pathogen is destroyed, while memory cells will last a long time and they 
will be responsible for protecting the individual against new infections caused by the same pathogen. (D) When the memory cells are subjected to multiple cycles of 
activation by means of chronic antigens they can generate two types of T lymphocytes, exhausted T lymphocytes and senescent T lymphocytes. The principal 
characteristics of both cell types are shown in the figure.
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of these cells remains unchanged, but concomitant with a decrease 
in their count after being exposed to high concentrations of 
pro-inflammatory cytokines (27–29). A few recent studies have 
shown that the sensitivity of CD8+ T lymphocytes to antigens is 
greatly increased if cytokines, such as IL-12, IL-18, and IFN-γ, 
are present prior to antigenic recognition (30, 31). However, 
only a very few studies have approached the effect of persistent 
inflammation on naive T lymphocytes, as it occurs in the context 
of aging or in the pro-inflammatory tumor microenvironment. 
Most of them suggest that there is a loss in the number of naïve 
T lymphocytes and a decrease in their functionality, although it 
is not clear the molecular mechanisms involved and more studies 
must be carried out (3, 32).
Clonal expansion in Response  
to Specific Antigens
Naïve T lymphocytes present an amazing capacity to react against 
specific antigens through massive proliferation and differentiation 
to effector T lymphocytes. They are able to migrate to the infec-
tion sites and eliminate the triggering pathogen. Encounter with 
the antigen takes place in the secondary lymphoid organs, where 
APCs show them to the T lymphocytes. Then, a differentiation 
process begins; it is destined to produce large amounts of effec-
tive cells to fight against the pathogen with a clonal proliferative 
process but without coming to exhaustion. Interaction between 
T  lymphocytes and APCs continues in tissues and so does the 
expansion and cellular differentiation, in an effort to contain the 
infection without damaging the tissues of the affected individual. 
Therefore, antigenic recognition by T  lymphocytes provides a 
series of changes that leads to a clonal expansion of differentiated 
and effective T  lymphocytes. The activation of T  lymphocytes 
through its specific TCR can be detected seconds after antigenic 
contact, and it continues during hours and days in the context of 
pathology (33, 34) (Figure 2B).
The activation of lymphocytes after recognizing a peptide in 
the context of a MHC molecule (priming of naïve T lymphocytes) 
FiGURe 3 | Acute and chronic inflammation participation in antitumor 
responses. When acute inflammation is activated by tumor cells, Th1 cells 
secrete antitumor cytokines, such as IFN-γ and IL-2, which, together with 
antitumor antibodies produced by B lymphocytes, exert an antitumor 
response and lead to tumor rejection, attracting innate immune cells and 
cytotoxic T lymphocytes. However, when chronic inflammation occurs in 
response to tumors, there is often an increase in regulatory T lymphocytes, 
Th2 cells, and activated B lymphocytes that secrete growth factors, such  
as IL-4, IL-6, IL-10, IL-13, TGF-β, and immunoglobulins that decrease both 
antigenic presentation and the activation of cytotoxic cells, favoring tumor 
progression.
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carries a series of processes of various types (genetics, prolifera-
tive, differentiation, biochemical) that lead to the formation of 
specific clones of effective lymphocytes, some of which will 
remain for long time in the form of memory cells. Before antigen 
exposure, the frequency of naive T lymphocytes specific for any 
antigen is 1 in 105 to 106 lymphocytes. After antigen exposure, 
the frequency of CD8+ T lymphocytes specific may increase to 
as many as 1 in 3 CD8+ T lymphocytes, representing a >50,000-
fold expansion of antigen-specific CD8+ T lymphocytes, and the 
number of specific CD4+ cells increases up to 1 in 100 CD4+ 
lymphocytes may increase up to 5,000-fold.
It is well known that the single contact of T lymphocyte with 
its antigen is not enough to generate a cellular response but it 
rather causes the cell to enter into a refractory state and does not 
respond to any stimulus (35). This discovery led to the hypothesis 
that there should be other additional stimulatory signals that 
would enable T lymphocytes to become activated and exert their 
functions. Thus, when the CD28 molecule was identified as a 
co-stimulator of T lymphocyte function, the theory of the “two 
signals” was then reported, these two signals being necessary for 
the T lymphocytes activation. However, numerous evidences have 
suggested that other membrane-bound and soluble inflammatory 
signals are necessary to complete the activation of T lymphocytes, 
thus enforcing the “three signals” and “four signals” alternative 
theories. All experimental data seem to highlight the significant 
role of inflammatory mediators in the process of T lymphocytes 
differentiation into the effector population, resulting in a more 
adequate tool to respond to the aggression suffered (36, 37). On 
the other hand, there is also a great deal of data suggesting that 
TNF superfamily receptors (CD30, 41BB, OX-40, CD27) interact 
with their ligands in APCs (CD30L, 41BBL, OX-40L, CD70), 
which favors the survival of the activated cells and their passage 
into memory cells (38, 39).
T  lymphocytes also have a large number of inhibitory mol-
ecules that help to regulate the cellular response, in a way that 
keeps this response not to be exaggerated and that would end 
up being harmful to the body. These inhibitory molecules act 
both, by limiting the co-stimulatory signals and by binding to 
the appropriate co-stimulatory receptors. The main inhibitory 
receptors belong to the CD28 family, including cytotoxic T lym-
phocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), 
both being involved in the phenomenon of tolerance. CTLA-4 
is an inhibitory molecule expressed in activated T lymphocytes 
which causes an increase in the intracellular phosphatase activity, 
thus producing a decrease in the signals generated by the TCR 
and CD28 molecule. On the other hand, CTLA-4 acts also as 
a competitive receptor for the CD80/CD86 receptor, but with a 
higher affinity for these receptors than CD28 itself (40, 41). As a 
result, depending on their level of expression on the cell surface, 
CTLA-4 may interfere with CD80/CD86 binding. Several more 
inhibitors, such as lymphocyte activation gene 3, and V-domain 
Ig suppressor of T  lymphocyte activation have been described, 
blocking these inhibitors by specific antibodies are being studied 
to increase the immune response in numerous cancers (42, 43).
The scenario in which the T lymphocyte response occurs may 
change in  situations such as aging or in tumor microenviron-
ment, where systemic or local inflammation is present (Figure 3). 
The levels of pro-inflammatory cytokines, such as IL-6, IL-1β, 
TNF-α, or GM-CSF, increase in these cases and this influences 
the lymphocyte response (3, 44). Dendritic cells are essential for 
T lymphocytes to be activated and differentiated as they present 
the antigen, producing co-stimulatory signals and essential 
cytokines. All these processes are highly dependent on the 
inflammatory environment mainly in chronic situation (45, 46). 
In the immune response during aging, myeloid dendritic cells in 
inflammatory environments have a decreased ability to present 
the antigens to CD4+ and CD8+ T lymphocytes (47). Moreover, 
most studies describe a reduced ability to produce cytokines by 
dendritic cells stimulated through toll-like receptors in  vitro, a 
defect related to low response to vaccination in elderly (48, 49). 
TNF-α directly affects the immune response, in part by reducing 
the expression of the co-stimulatory molecule CD28 (50, 51). The 
pro-inflammatory environment may also be responsible for the 
attenuated response of T lymphocytes to cytokines, possibly due 
to the activation of negative regulatory pathways (4). According 
to the inflammatory environment in which lymphocytes are, the 
polarization of T lymphocytes will be different. In inflammatory 
environments, there is no evidence that Th1, Th2, or Th17 cells 
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are diminished, but follicular T  lymphocytes have been found 
to be less common in the elderly with systemic inflammation in 
response to vaccination (52, 53). It has been shown that CD4+ 
T lymphocytes activated in inflammatory environments are less 
responsive to type I interferons due to recruitment by the IFNR 
signaling complex of SHP1 (54). In conclusion, the inflamma-
tory environment must be taken into account when evaluating 
immune responses. Individuals with high systemic and/or local 
inflammatory levels, as it occurs in the elderly and in cancer 
patients, may have an impaired response to cytokines and a poor 
response to antigens. In these cases, an anti-inflammatory treat-
ment could be beneficial in trying to restore a correct immune 
response.
Maintenance of Memory T Lymphocytes
The T  lymphocyte-specific antigen response is characterized 
by clonal expansion, followed by a contraction in the number 
of specific cells and the formation of memory T  lymphocytes. 
In this process, T lymphocytes acquire many key features to afford 
protection against re-infections, which are potentially deadly. 
Memory T lymphocytes are found in greater numbers than naïve 
T lymphocytes and in the presence of IL-7 and IL-15 these cells 
can be maintained for long periods of time without antigenic 
stimulation (55, 56) (Figure 2C). Central and effector memory 
T lymphocytes are less dependent on the contact with the MHC–
peptide complex for survival than naïve T lymphocytes do (57). 
In addition, their self-renewal is three to four times faster than in 
naïve T lymphocytes and has a high proliferation rate in lympho-
penia (58). The large number of memory cells, their high ability 
to reactivate, produce cytokines, and kill after antigenic stimula-
tion and their distribution by almost all tissues makes memory 
T lymphocytes capable of protecting the individual much better 
than naïve T lymphocytes.
As previously mentioned, memory T lymphocytes can be divi- 
ded into two populations, effector memory cells (EM, CD45RA−, 
CCR7−) and central memory cells (CM, CD45RA+, CCR7+), 
but other subpopulations can be established from  the expression 
of CD27 and CD28 (5). EM are preferentially located in non- 
lymphoid and mucosal tissues and have a lower response thresh-
old than CM, which are found mainly in secondary lymphoid 
organs and have a greater expansion capacity than EM.
There is no unanimity to describe the way by which T lympho-
cytes become effector and central memory cells (59). The most 
convincing hypothesis suggest a developmental trend from naïve 
T lymphocytes to memory cells, in which most memory cells have 
gone through a phase of effector cells. Some effector cells might 
then evolve into memory cells since some microarray studies 
have shown that passage of naïve cells to effectors and memory 
is a gradual step (59–61). Besides, several laboratories have used 
murine models of labeled effector T lymphocytes to track them, 
showing that most memory cells have indeed derived from these 
effector cells (62, 63). Thus, at least a set of memory cells that 
appear after an infection are generated from the effector cells.
Numerous studies have shown that exposure to a restricted 
inflammation increases the appearance of memory-like 
T lymphocytes when the intensity of inflammatory signals is 
controlled (59, 64). Several inflammatory molecules, such as 
interferon type I and IL-12 can be considered to act as the third 
signal (in addition to TCR and co-stimulation) and thus, to 
promote differentiation of T lymphocytes to effector cells (65).
According to several studies, prolonged and/or intense expo-
sure to the pro-inflammatory cytokine IL-12 promotes a prefer-
ential differentiation toward effector cells, rather than memory 
cells (66, 67). The effect of other inflammatory molecules on 
T  lymphocytes may be indirect. For instance, an interesting 
study found a blockage in the contraction of T lymphocytes when 
there was a deficiency of IFN-γ (68). In this scenario, we believe 
that IFN-γ offers a competitive advantage for the appearance of 
memory T  lymphocytes, in some types of immune responses 
(69). Some studies suggest that at least some level of inflamma-
tory signal is necessary for the differentiation to memory T lym-
phocytes. T  lymphocytes deprived of this inflammatory signal 
(third signal) or deficient in T-bet transcription factor showed 
a decreased ability to produce long-lived memory cells. T-bet is 
needed for the expression of the CD122 molecule, that is the beta 
chain of the cytokine receptors IL-15 and IL-2, and to be able to 
react to homeostasis mediated by IL-15 (66, 70, 71). The cytokine 
IL-15 not only can promote the division and proliferation of dif-
ferentiated and memory T lymphocytes but it is also capable of 
increasing its functional capacities (72, 73).
The differentiation of memory T lymphocytes in the course of 
chronic infections or in the presence of persistent antigens (auto-
immune diseases, tumors, or atherosclerotic diseases) is different 
from differentiation in acute infections and leads to a defect in 
the functionality of T  lymphocytes. These cells phenotypically 
acquire expression of several typical cytotoxic cell markers, such 
as NKG2D, PD-1, CD56, CD16, KLRG1, etc. (74, 75). Unlike 
memory cells generated after the elimination of an acute infec-
tion, memory cells in situations where the antigen is present in a 
chronic form, and in an inflammatory environment, proliferate 
and increase in number because the continuous stimulus (76, 77). 
These subpopulations, in turn, have propensity to secrete pro-
inflammatory cytokines, such as IFN-γ, IL-1, TNF-α, and IL-6, 
contributing to increase the systemic or local inflammation (78).
New encounters with Specific Antigens 
and Telomere Maintenance
One of the most remarkable characteristics of the immunological 
memory system is the capacity of the antigen-primed T lympho-
cytes to carry out a rapid response after they encounter the same 
antigen again (79). Co-stimulation signals have been recognized 
as critical for optimal T  lymphocyte responses and result from 
important interaction between receptors on the surface of T lym-
phocytes and their ligands on APCs. However, memory T lym-
phocytes exhibit more reduced dependency to co-stimulation, 
and a significant lower threshold to respond.
T lymphocytes must be able to grow exponentially upon the 
first, and especially the second and the following, encounter with 
an antigen, and when they are no longer needed some of them enter 
apoptosis and disappear. Like most normal cells, lymphocytes are 
able to pass through a limited number of division cycles. Limited 
number of cell cycle divisions is associated to cell senescence or 
cell stress, which ends up in cell death triggering. Similar to what 
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occurs to normal cells that evolve toward a neoplastic state acquir-
ing a high rate of proliferation, lymphoid cells are also able to con-
stitutively activate telomerase (80). Upregulation of telomerase and 
consequently elongation of telomeres allows extending the cells 
lifespan (81, 82). When the mechanisms that compensate telom-
eric shortening disappear and when shortening reaches a critical 
point known, cells enter a state of growth arrest termed senescence 
(83, 84). Telomere size can be determined by analyzing the ter-
minal restriction fragments (TRF) that contains the TTAGGG 
region. The length of the TRF varies depending on cell population 
and each chromosome within the same cell. The critical point for 
cells to enter senescence appears when the size of TRFs reach 
less than 6 kb (85). The overall finding from different studies is 
that T  lymphocytes in humans can carry out a certain number 
of divisions, after which they can no longer be divided (86, 87). 
Importantly, the reach of the replicative senescence stage by 
T lymphocytes does not imply a loss of cell viability. Moreover, 
senescent T  lymphocytes under suitable conditions can remain 
alive and metabolically active for a prolonged period of time 
(88, 89). This transitional state of lymphocytes is not, however, 
shared with stem cells or malignant tumor cells, which do not 
reach replicative senescence and have stable chromosomes despite 
intense division. Stem and malignant T  lymphocytes maintain 
telomerase activity and, therefore, replicative capacity throughout 
their lives (90). Nevertheless, by using mice lacking telomerase, 
it has been demonstrated that telomere shortening shunts 
 premalignant T lymphocytes into the senescent state, therefore, 
reducing tumorigenesis (91).
It is very important to distinguish undifferentiated and highly 
differentiated T lymphocytes in order to study telomerase activity 
in these two populations. The undifferentiated T  lymphocytes 
(CD27 +CD28+) display longer telomeres than highly differenti-
ated T lymphocytes (CD27−CD28−) while intermediate popula-
tions (CD27−CD28+ or CD27+CD28−) have telomere lengths 
between both, undifferentiated and highly differentiated cells 
(92, 93). In addition, the proliferation ratio in T lymphocytes is 
higher in highly differentiated CD45RA−CCR7− cells that have 
a lower telomeric length (92, 94). Telomerase activity correlates 
with the length of telomeres, thus this activity is greater in the 
more undifferentiated cells and much lower in the cells with high 
differentiation. In addition, as the cell ages, the ability to induce 
telomerase expression and activation is lost (92, 93, 95). Moreover, 
differences in the behavior of telomerase have been found between 
CD4+ and CD8+ T lymphocytes. Cultures of CD4+ and CD8+ 
T lymphocytes from the same subject that have encountered an 
antigen for the fourth time were unable to increase telomerase 
production. However, the CD4+ T lymphocytes had much higher 
telomerase activity than that of the CD8+ T lymphocytes from the 
same donor (96). Several studies have shown that homeostasis of 
CD4+ T lymphocytes is much more rigorous than that presented 
by CD8+ T lymphocytes. In addition, aging in lymphocytes was 
previously described in CD8+ T lymphocytes, since the changes 
observed in immunosenescence occur much earlier in these 
CD8+ T lymphocytes (97–99).
The signaling via the TCR and the co-stimulation with other 
molecules such as CD28 is essential for the induction of telomer-
ase activity. This activity peaks 4–5 days after the TCR has been 
stimulated, but presents a decrease in its activity after 10  days 
(92, 100, 101). T lymphocytes can proliferate under stimulation of 
various cytokines without the mediation of TCR. This is homeo-
static proliferation, the mechanism by which naïve and memory 
T lymphocytes are maintained in the periphery (8). The cytokines 
IL-7 and IL-15 have been related to telomerase activity in the 
CD4+ and CD8+ T  lymphocytes, respectively (102, 103). Our 
laboratory has demonstrated that IL-15 has a preferential effect 
on the CD4+CD28− T lymphocyte population, which causes an 
increase in proliferation and specific responses of these cells (73). 
It has also been found inhibitory effects on telomerase activity by 
some cytokines such as IFN-α and TGF-β (104, 105).
Factors that promote repeated T lymphocyte stimulation, such 
as persistent antigen and chronic inflammation, appear to drive 
telomere loss and replicative senescence. Elderly individuals and 
cancer patients, often exhibit chronic inflammation characterized 
by immune system dysregulation with increased inflammatory 
cytokine production (73, 74, 106, 107) and redox imbalance due 
to reduced antioxidant defenses and overproduction of reactive 
oxygen species (ROS) (108). It is now recognized that chronic 
inflammation is a major risk factor for several age-associated dis-
eases, including chronic obstructive pulmonary disease, neuro-
degeneration, obesity, and vascular disease (109, 110). Premature 
telomere erosion in peripheral blood lymphocytes is a common 
characteristic of these diseases as well as autoimmune syndromes 
(103). These findings suggest that telomere loss increases suscep-
tibility to autoimmune disease and may be a predisposing factor 
for age-related inflammatory disease.
Restoring telomerase activity in T  lymphocytes would have 
a great impact on human lives by restoring telomere shortening 
and, in turn, avoiding the deleterious effects of aged T lympho-
cytes. Several studies have shown that if the telomerase activity 
is preserved, the telomeric length is stabilized and replicative 
senescence can be delayed (111, 112). One possible solution to 
stimulate telomerase activity would be to eliminate senescent 
T lymphocytes from the bloodstream or bring them into apopto-
sis. Telomere loss could be stopped by inhibiting cytokines, such 
as TNF-α, mediating telomere shortening.
T Lymphocyte exhaustion
In a viral infection or cancerous environment where there is a 
permanent exposure to certain antigens and high inflammation, 
memory cells are highly affected (113). This alteration, known 
as T cell exhaustion, presents a series of characteristics: progres-
sive loss of effector functions, upregulation and co-expression 
of many inhibitory receptors, alteration of transcription factors, 
dysfunctional metabolism, failure to enter a quiescent state, and 
response to normal homeostasis (114) (Figure 2D). Although the 
appearance of exhausted T lymphocytes was first described in an 
environment of viral infection, it has also been observed in the 
presence of cancer and in various inflammatory diseases. Initially, 
exhausted T lymphocytes have a defect in proliferative progres-
sion and a defect in the expression of telomerase, but the rest of 
their functions are completely conserved (115). Next, exhausted 
T  lymphocytes, mainly due to continuous antigenic stimula-
tion and a pro-inflammatory environment, enter into a state of 
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differentiation where they gradually lose their effector functions, 
such as cytokine production and cytotoxic capacity, which pre-
vents these cells from being effective against cancer or microbial 
infections (113). Exhausted T lymphocytes normally arise during 
high-grade chronic infections in highly pro-inflammatory envi-
ronments, where the level and duration of antigenic stimulation 
are critical for this process to occur (116, 117).
Viral infections and cancerous tumors can cause the appear-
ance of exhausted T  lymphocytes, but not all cases lead to an 
exhausted T  lymphocyte (113, 118, 119). The difference in the 
ability to produce exhausted T lymphocytes may be due to dif-
ferent T lymphocyte specificities. The most effective specificities 
in stopping pathogens inactivate them faster and destroy them 
quickly. Exhausted cells regain functionality and become typical 
memory T lymphocytes when viral infection is under control and 
in turn, antigen concentration decreases (120).
Exhaustion of T lymphocytes is accompanied by an increase 
in expression of inhibitory molecules, including PD-1, CTLA-4, 
LAG3, 2B4, CD160, and T  lymphocyte immunoreceptor with 
immunoglobulin and ITIM domains (TIGIT). PD-1 is an 
inhibitory protein that intervenes in self-tolerance by inhibiting 
the activation of T  lymphocytes using a similar mechanism as 
describe for CTLA-4 (121). After PD-1 interaction with its 
ligands, namely PD-L1 or PD-L2, TCR signaling is blocked by 
recruiting SHP-2 phosphatase and subsequent dephosphorylat-
ing of the antigen receptor (122). Interestingly, both ligands are 
often overexpressed in many tumor cells, but PD-1 is highly 
expressed in T lymphocytes from patients with different types of 
cancer. PD-1 ligand levels from tumor cells and PD-1 levels from 
T lymphocytes are usually correlated with the tumor aggressive-
ness and poor prognosis (121).
The proliferation of exhausted cells is partially compensated 
with PD-1 suppression, but telomerase activity is not restored 
(123). Many causes leading to T  lymphocyte exhaustion are 
shared with those leading to T lymphocyte aging. Several epige-
netic studies in naïve and central memory T lymphocytes reveal 
an age-associated loss of access of T lymphocytes promoters to 
their chromatin site of action, particularly to the NRF1-binding 
sites (124). This loss seems to intervene in the reduced expression 
of the genes of the mitochondrial respiratory chain and, there-
fore, in the deficient oxidative phosphorylation that can lead to 
death of the T  lymphocytes (125). Repression of the molecule 
PGC1α, a cofactor of NRF1 activity, is an event that appears early 
in exhausted T  lymphocytes, indicating a mechanistic overlap 
between T  lymphocyte aging and exhaustion (126). Effector 
memory T lymphocytes of elderly individuals compared to 
effector memory cells in young people show few differences with 
respect to the accessibility of chromatin promoters. Thus, the 
memory T lymphocytes in elderly individuals do not exhibit the 
epigenetic marks of the exhausted T lymphocytes (124, 127). This 
observation may indicate that T lymphocyte aging affects mainly 
to naïve cells and central memory, possibly through pathways 
similar to those involved in T  lymphocyte exhaustion. On the 
other hand, effector T  lymphocytes in the elderly do not show 
any signs of exhaustion.
The epigenetic phenotype of the exhausted T  lymphocytes 
remains stable when PD-1 is blocked and the restoration of 
function is, therefore, only transient in most T  lymphocytes 
(128). This evidence leads us to consider whether treatment 
with PD-1 blockers decreases along with age due to aging of the 
exhausted T lymphocytes or rather because the responsive frac-
tion of exhausted T lymphocytes to treatment decrease with age.
The appearance of exhausted T  lymphocytes prevents the 
possibility of an adequate control of infections and malignant 
tumors. Therefore, if overexpressing pathways in the exhausted 
T  lymphocytes could be modulated, for example, by inhibiting 
PD-1 and CTLA-4, their dysfunctional state could be reversed 
and immune responses invigorated.
MeTABOLiC RePROGRAMMiNG
T  lymphocytes must carry out metabolic strategies throughout 
their differentiation process and because of the changing micro-
environment in which they are located. The purpose of these 
adaptations is to meet energy and structural needs in the differ-
ent stages of proliferation and to achieve functional responses 
according to the availability of nutrients.
Naïve T  lymphocytes, since they exit the thymus as mature 
cells and during their travel throughout the secondary lymphoid 
tissues until encountering their specific antigen, show a reduced 
rate of cell division. Even more, it is considered that they are in 
a functional quiescence, which does not require a high-energy 
consumption. They use the available nutrients trying to obtain 
the highest energy yield. Glucose, fatty acids, and amino acids 
are metabolized until they enter into the tricarboxylic acid (TCA) 
cycle where ATP and reducing equivalents are generated, which 
subsequently increase the production of ATP upon entering the 
pathway of oxidative phosphorylation (129, 130).
When naïve T  lymphocytes encounter APCs carrying their 
specific antigenic peptide, activation takes place in a lymph 
node. Clonal expansion of the antigen-specific T  lymphocytes 
is mainly mediated by IL-2 and the subsequent functional 
differentiation adapts the response to the specific triggering 
pathogen. Proliferation leads to generate sufficient amount of 
specific T lymphocytes capable of eradicating the pathogen. Thus, 
T  lymphocyte activation not only requires energy but also the 
production of precursors that support the explosive proliferation 
through the biosynthesis of the required cellular components, 
proteins, lipids, nucleic acids, etc. These processes imply a high 
increase in energy demands, resulting in a switch in the metabolic 
pathways of nutrient utilization. Initially, there is an increase in 
glucose uptake, by increasing the expression of glucose trans- 
porter (GLUT) such as GLUT-1 (131). Glucose is, therefore, 
essentially metabolized to lactate by aerobic glycolysis, a 
phenomenon known as “Wargurg Effect,” which was initially 
described in tumor cells and, more recently, also in T lympho-
cytes (132–134). It is currently considered that “T  lymphocyte 
activation-induced metabolic reprogramming is reminiscent of 
the metabolic changes associated with oncogenic transformation” 
(135, 136). More than 90 years ago, Otto Warburg described that 
tumor cells, even in the presence of oxygen, showed a high rate of 
glycolysis. This so-called aerobic glycolysis is now recognized as 
one of the new hallmark of cancer capabilities (5). In differenti-
ated cells, glucose renders through the TCA cycle an energetic 
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yield of 36 molecules of ATP. And yet, cancer cells rather prefer 
to compromise a high ATP production in order to obtain other 
benefits, in terms of building blocks for their new daughter cells 
(137–139). Recently, a similar program has also been observed 
in all proliferative cells including T  lymphocytes upon antigen 
activation. This metabolic adaptation ensures a high glycolytic 
rate, which is not inhibited by the production of mitochondrial 
ATP. Moreover, glycolysis inhibits apoptosis and contributes to 
the maintaining of mitochondrial membrane potential (137, 140). 
Regarding the immune system, metabolic reprogramming has 
also been linked to the acquisition of certain functional proper-
ties by T lymphocytes such as the secretion of IFN-γ (134, 141).
Other functional parallelism found is glutaminolysis, which 
also increases in response to T lymphocyte activation as well as 
after transformation of cancer cells. Glutamine is rapidly con-
sumed by tumor cells, playing a key structural role as a nutrient in 
the biosynthesis of nucleotides. The concentration of glutamine 
has been shown to be limiting in the progression of the cell cycle. 
Glutamine deprivation leads to cell cycle arrest in some cell types. 
Glutamine is not only an important source of carbon and nitro-
gen for the synthesis of other amino acids but the α-ketoglutarate 
generated is an anaplerotic substrate of the TCA cycle. Thus, it 
may contribute to the generation of ATP when glucose is primar-
ily derived toward this so-called aerobic glycolysis (142).
On the other hand, pentose phosphate pathway (PPP) is the 
main catabolic route that generates ribose, necessary for the syn-
thesis of nucleotides, and NADPH, essential for proliferation as it 
provides the reduction equivalents for fatty acid and cholesterol 
biosynthesis. Furthermore, PPP plays an essential role in balanc-
ing the redox status by regulating the production of glutathione 
(143). The utilization of PPP is usually elevated in cancer cells and 
in proliferative T lymphocytes. The key enzymes in the pathway 
are overexpressed in cancer and oncogenes and tumor suppres-
sors have been shown to regulate PPP activity.
Metabolic decisions are dependent on the co-stimulatory 
signals received by T lymphocytes, in particular on CD28, which 
mediates many of these processes via the PI3K–Akt–mTOR path-
way. However, in cancer cells intracellular programs combine 
with extracellular signals, to achieve a significant independence 
from external requirements. Genetic alterations as common as 
PI3K and its negative regulator PTEN as well as gen amplifica-
tions of upstream receptor tyrosine kinases result in an increase 
in glucose uptake and in the metabolic reprogramming in several 
cancer cells (144). It is noteworthy to mention that the metabolic 
state of cancer cells has a potential influence on the surrounding 
cells. Thus, within the tumor microenvironment, cancer cells alter 
the metabolic composition of the extracellular milieu, affecting 
the signaling pathways that influence the infiltration of immune 
cells, including T infiltrating lymphocytes. mTOR is a central part 
of various signals that come from the immune microenvironment 
because mTOR works as a sensor of extracellular medium condi-
tions. mTOR is an evolutionarily conserved serine/threonine 
kinase, which forms two complexes, mTORC1 and mTORC2, 
determined by the association with different adapters and scaf-
folding proteins. mTOR is responsible for integrating different 
responses upon receiving environmental signals and for the con-
trol of various cellular functions, such as growth, apoptosis, actin 
reorganization, metabolism, and ribosome genesis (145, 146). 
mTOR activation targets T  lymphocyte metabolism, switching 
it toward glycolytic metabolism by induction of two major 
transcription factors, namely HIF1α and c-MYC (147, 148). 
HIF1α is stabilized under hypoxia but it can also be activated by 
mTOR even under aerobic conditions. It increases the expression 
of GLUTs and glycolytic enzymes, such as pyruvate dehydroge-
nase kinase 1, limiting the entry of pyruvate into TCA cycle and 
favoring its reduction to lactate. The deregulation of multiple 
elements of the mTOR pathway has been reported in many types 
of cancers, implying significant effects on tumor progression. 
Likewise, mTORC1 signaling controls transcription of many 
genes, some of which are involved in metabolic and biosynthetic 
pathways (149).
Signals derived from anaerobic conditions and nutrients 
availability may modulate the cytokine profile of T lymphocytes 
(150). CD4+ T lymphocyte differentiation into a specific effector 
phenotype (mainly Th1, Th2, Th17, Treg) will depend fundamen-
tally on the cytokines present in the immunological microenvi-
ronment at the time of antigenic presentation. mTOR plays a key 
role in the differentiation into the effector phenotypes, but not 
into Treg, so mTOR1 is needed for differentiation toward Th1 and 
Th17, whereas mTOR2 regulates Th2 differentiation (151). Thus, 
mTOR coordinates the metabolic pathways and the differentia-
tion of each subpopulation of CD4+ T lymphocytes (146). High 
levels of HIF1α direct the CD4+ T lymphocyte metabolism to the 
glycolytic pathway, favoring the activation of RORγt transcrip-
tion factor and its differentiation toward a Th17 inflammatory 
phenotype. Inhibition of this pathway, even under conditions 
that promote Th17 differentiation, results in Treg lymphocytes 
(152, 153). Th1 also possess a high glycolytic rate, concomitant 
with a higher surface location of GLUT1 (154). In fact, there is a 
coordinated regulation between T  lymphocyte metabolism and 
the IFN-γ production by Th1. GAPDH is attached to UA-rich 
regions located at the 3′ in the untranslated region of the IFN-γ  
mRNA in non-activated cells. When glycolytic metabolism 
is activated, this enzyme is involved and does not bind to the 
mRNA, allowing its translation and IFN-γ production (134).
It has also been shown that the limited availability of glutamine 
in the extracellular medium favors Treg differentiation, even in 
the presence of cytokines involved in Th1 differentiation (155). 
The reason seems to be the decrease in intracellular levels of 
α-ketoglutarate, a mTORC1 activator, the expression of T-bet tran-
scription factor and, as a result, differentiation into Th1. Similarly, 
the production of GLUT1 receptor, essential for the development 
of Th1 responses, is increased, whereas Tregs are unaffected by 
deficiency in this receptor and maintain their inhibitory capacity 
on T lymphocytes independently of GLUT1 (156).
In CD8+ T  lymphocytes, mTORC1–HIF1α is activated by 
a PI3K–Akt-independent pathway, through phosphoinositide-
dependent kinase 1. Metabolically, it promotes the activity of 
glycolytic enzymes and at functional level, it activates cytolytic 
capacity, controls the migration, and inhibits the generation of 
memory cells. Meanwhile, mTORC2 activates oxidative metabo-
lism (157, 158).
In other way, long-lived specific memory cells that circulate 
between the secondary lymphoid organs, blood, and tissues 
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do not proliferate significantly and have a quiescent functional 
state with scarce or no cytokine production. The main difference 
with naïve cells is that memory cells need to be prepared to 
respond quickly and efficiently to a new contact with the anti-
gen. Their metabolism is based on the oxidation of glucose and 
fatty acids and they are characterized by a high content of large 
mitochondria, which are generated by fusion of the individual 
organelle that support the energetic requirements in reactivations 
(159, 160). In addition, ATP obtained from glucose oxidation 
is used to synthesize fatty acids, which in turn will be oxidized. 
The motive of this futile cycle could be the maintenance of the 
mitochondrial activity in order to be ready to respond quickly to 
specific-antigen re-stimulation (161–163).
Following multiple antigenic challenge, mainly in the case of 
chronic viral and tumor antigens and in  situations of  chronic 
inflammation, the specific T lymphocytes go through successive 
phases of clonal division, which as mentioned above, changes 
its degree of differentiation and, in parallel, its phenotype and 
functional capacity. In this stage, metabolic switching occurs in 
favor of an oxidative phenotype and is unambiguously associated 
with increased mitochondrial ROS production. On the other 
hand, inhibition of fatty acid oxidation decreases NADPH and 
glutation (GSH) levels. However, ROS levels increase, suggesting 
that control of fatty acid oxidation, in addition to PPP, regulates 
NADPH levels, which is essential to regenerate GSH pools from 
the glutathione disulfide (164, 165).
Finally, T  lymphocytes reach replicative senescence, char-
acterized by constitutive p38 mitogen-activated protein kinase 
activation, telomeric shortening, the loss of telomerase activity, 
and reduced proliferative capacity in response to stimulation 
(123). This new situation is also associated with metabolic 
adaptations. Again, a link between T  lymphocytes aging and 
bioenergetic status has been proposed, since glucose deprivation 
in non-senescent T lymphocytes induces the activation of p38, 
and its constitutive activation inducer, the metabolic sensor of 
intracellular levels of ATP AMPK (5′-monophosphate activated 
protein kinase). These processes lead to a reduction in telomerase 
activity and proliferation similar to those observed in senescent 
T lymphocytes (166, 167). The main metabolic pathway used by 
these cells at this stage is glycolysis. Senescent T  lymphocytes 
show mitochondrial dysfunction and consequently produce 
higher levels of ROS and defective mitochondrial biogenesis, 
which may justify their metabolic switch. P38 inhibition leads to 
mitophagy and thereby nonfunctional mitochondria are elimi-
nated and ROS production is reduced. However, the increase in 
energy needed to sustain proliferation continues to be obtained 
from glycolysis and not from oxidative phosphorylation (168). 
As mentioned previously, high levels of inflammation in certain 
chronic viral infections and in cancer, induces an exhausted 
stage, similar to happen in senescence (113, 169, 170). There 
are numerous links between the inhibition of T lymphocytes by 
CTLA-4 and PD-1 and metabolic signaling pathways. CTLA-4 
interacts with PP2A (protein phosphatase 2), a negative regula-
tor of AKT, mTOR, and MAPK signaling, whereas PD-1 inhibits 
AKT phosphorylation by preventing CD28-mediated activation 
of PI3K (171). It has been shown that PD-1 inhibits glycolysis and 
amino acid metabolism and promotes lipid metabolism, whereas 
CTLA-4 inhibits both processes and mitochondrial biogenesis 
in memory cells (172, 173). Since the main metabolic pathway 
of T  lymphocytes during activation is the aerobic glycolysis, 
these molecules could be blocking differentiation into effector 
T  lymphocytes, at least partially, by metabolic regulation. The 
increase in β-oxidation of fatty acids could be an explanation for 
the maintenance of these cells, despite being exhausted, and in 
addition to its ability to recover functionality when interaction 
between PD-1 and its ligands hangs (173). Figure  4 shows a 
diagram of the main lymphocyte metabolic pathways in their 
different differentiation stages.
ReDOX CONTROL OF CeLLULAR FATe
Relationship between oxidative stress and inflammation has been 
widely documented (174). Oxidative stress plays a pathogenic 
role in many chronic inflammatory diseases. Lower levels of GSH, 
an intracellular thiol antioxidant, causes ROS production, which 
results in imbalanced immune response and inflammation. 
Moreover, protein oxidations turn into release of inflammatory 
signal molecules and inflammatory stimuli induce the release of 
peroxiredoxin 2, a redox-active intracellular enzyme (175).
Basal levels of ROS generated in response to endogenous and 
exogenous stimuli are crucial mediators of multiple cell processes 
such as growth, differentiation, or migration, but excessive pro-
duction might induce cell death, apoptosis, and/or senescence. 
Oxidative stress triggered by the excessive ROS production, cause 
oxidative damage to cellular components such as DNA, proteins, 
or lipids, which is closely related to the pathogenesis of various 
diseases including cancer. In addition to exogenous ROS, major 
intracellular sources of ROS are NADPH oxidases and particu-
larly mitochondria. Usually, physiologically generated ROS are 
balanced by non-enzymatic and enzymatic systems, such as, 
GSH, superoxide dismutases (SOD1/2), thioredoxins (Trx1/2), 
catalase, or peroxidases. In addition, NADPH, is one of the main 
thiol-dependent electron donors system in the cell and plays a 
critical role in the regulation of cellular redox environment and 
in a wide range of cellular pathways, including activation of tran-
scription factors such as NF-κB, activator protein-1, p53, HIF-1, 
or the redox factor 1 (176). Elevated levels of ROS production 
have been considered an adverse event, playing an important 
role in tumor initiation and progression, but also in promoting 
inflammatory environments. However, ROS are now more widely 
recognized as important signaling molecules (177, 178). Redox 
signaling in cells by ROS such as hydrogen peroxide (H2O2) 
occurs through the reversible oxidation of cysteine thiol groups. 
A major cellular target of ROS is the thiol side chain (RSH) of 
cysteine, Cys sulfenic (Cys-SOH) and sulfinic (Cys-SO2H) acids 
have emerged as important mechanisms for regulation of protein 
function. These residues modifications result in reversible struc-
tural alterations that can modify protein function, which may 
imply either inactivation or gain of function (179).
The importance of ROS in immunity is exemplified by their 
generation and release in the form of an “oxidative burst” by 
phagocytic cells as part of the innate immune cell network to effec-
tively destroy pathogens and clear debris. However, ROS exert, as 
it does in other cells, a dual role on T lymphocyte biology. Mild 
FiGURe 4 | Main metabolic pathways of lymphocyte subpopulations. Naïve, memory, and regulatory T lymphocytes uptake low levels of glucose which it is 
metabolized by glycolysis and then the pyruvate generated is fully oxidized to CO2 in the mitochondria by the Krebs cycle. In contrast, effector lymphocytes  
have a large demand for glucose to maintain the biosynthetic processes that facilitate cellular growth, proliferation, and the synthesis of substantial quantities  
of effector molecules. Thus, effector lymphocytes show higher production of glucose transporters (GLUTs) and higher activity of glycolytic enzymes that facilitates 
elevated rates of glucose uptake and glycolytic flux. To sustain high rates of proliferation, pyruvate is converted to lactate and released out of cells. This prevents  
the accumulation of pyruvate which could result in the inhibition of the glycolysis pthway. Due to the high levels of glycolytic flux, glycolytic intermediates can be 
diverted into biosynthetic pathways to generate amino acids, lipids, and nucleotides in order to generate biomass. Senescent T lymphocytes use glycolysis 
extensively, partly because they have dysfunctional mitochondria and exhausted T lymphocytes mainly use lipid metabolism to carry out their poor cellular functions.
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ROS are essential for T  lymphocyte activation, expansion, and 
effector function (180–183). Still, elevated rate of ROS production 
or exposure and defective neutralization by antioxidant cellular 
systems, causes oxidative stress that compromises T lymphocyte 
proliferation and activity (182, 184). Balance between both situ-
ations may be fragile and the studies yield results that seem to be 
contradictory, probably due to different experimental conditions.
Regulatory effect of Oxidation  
on T Lymphocytes
Generation of ROS and Ca2+ release from intracellular stores are 
direct consequences of TCR/CD28 stimulation. Both are essential 
for TCR signaling, particularly in activation-induced CD95L 
expression (185). 5-lipoxygenase, NOX-2 and mitochondrial 
complexes are the most important sources of ROS in T lympho-
cytes (186–188). Oxidative signals originated from Complex I of 
the ETC regulate T lymphocyte activation-induced expression of 
IL-2 and IL-4, whereas Complex III is required for CD4+ activa-
tion and antigen-specific T  lymphocyte expansion (189, 190). 
It is well known that ROS can activate the transcription factor 
NF-κB, whereas chronic exposure to oxidative stress inhibits its 
phosphorylation and the activation of T lymphocytes (191, 192). 
Related to this, translocation of NF-κB to the nucleus occurs in 
a cytoplasmic oxidative environment; however, binding to DNA 
requires reducing environment. Very high levels of ROS might 
affect both compartments and in such circumstances NF-κB 
pathway will be inhibited (193, 194). On the contrary, reduced 
ROS production is associated with decreased phosphorylation of 
JNK and NF-κB and, therefore, low IFN-γ and CD39 expression 
in CD8+ T  lymphocytes (195). Equivalent results have been 
found in other regulatory pathways, since the exposure to low 
levels of ROS stimulates mTORC1 while high concentrations or 
long-term ROS treatment decrease mTORC1 activity (196).
Reactive oxygen species are also implicated in T lymphocyte 
differentiation, and murine models with specific knockouts 
of NOX-2, such as gp91phox and p47phox, have been employed 
to test this association. p47phox deficiency leads to Th17 dif-
ferentiation, because mice p47phox−/− have diminished expres-
sion of T-bet, STAT-1, and STAT-4 transcription factors, but 
increased phosphorylation of STAT-3. Additionally, it has been 
FiGURe 5 | Susceptibility of T lymphocytes to oxidative stress. Effector  
cells are exposed to low oxidative environment, while memory cells are 
T lymphocytes found in the most oxidative environments. The ability of 
T lymphocytes to stand such oxidative conditions, in either an infectious 
disease state or a tumor microenvironment, might determine the pool of 
T lymphocytes.
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shown a reduced production of IL-2, IL-4, IFN-γ, TNF-α, and 
GM-CSF, but increased IL-10, IL-17, and TGF-β (188). On the 
contrary, lack of gp91phox leads to a Th1 phenotype with reduced 
GATA-3 expression and STAT-5 and STAT-6 phosphorylation 
but increased T-bet expression. These T  lymphocytes produce 
less IL-4 and IL-5 but more IL-17 and IFN-γ (189, 197). Then, 
NOX-2-deficienT lymphocytes showed a decreased in IL-4 but an 
increased IL-17 production. Interestingly, NOX-2 is not required 
for the proper activation of primary murine T  lymphocytes, as 
gp91phox−/− T  lymphocytes have no defect in CD25 and CD69 
expression, IL-2 production, or proliferation (187, 197).
CD4 T  lymphocyte plasticity, switching from one lineage to 
another, may be affected by the oxidative microenvironment 
(37). As mentioned before, an oxidative microenvironment exerts 
opposite effects on cytokine secretion by Th1 compared to Th2 
cells. When in  vitro derived Th1 and Th2 clones or employed 
T  lymphocytes derived from autoimmune thyroiditis to exam-
ine their ability to expand and produce cytokines in response 
to oxidative stress, low levels of H2O2 are able to reduce IFN-γ 
production by activated Th1 clones but to increase IL-4 secretion 
by activated Th2 clones (198). Besides, mitochondrial ROS can 
control T  lymphocyte activation by upregulating IL-2 and IL-4 
expression, and using T lymphocytes isolated from patients with 
atopic dermatitis, the inhibition of Complex I-mediated ROS 
blocks disease-associated spontaneous hyperexpression and 
TCR-induced expression of IL-4 (189).
Oxidative Stress on T Lymphocytes
In opposite to regulatory role of mild oxidation, oxidative stress 
shows important effects during T  lymphocyte development 
and differentiation. Thymus-specific elevation of mitochondrial 
superoxide O 2•( )−  disrupts normal T  lymphocyte development 
and impairs the function of the mammalian adaptive immune 
system (199).
The stage of differentiation largely determines sensitivity of 
individual T lymphocyte subsets to oxidative stress. The suscepti-
bility of T lymphocytes to oxidative stress varies greatly depend-
ing on which stage of differentiation they are in (Figure  5). 
Effector cells are exposed to low oxidative environment, while 
memory cells are T  lymphocytes found in the most oxidative 
environments. Some secreted cytokines can cause oxidative 
stress in T lymphocytes and in cancer cells. For example, tumors 
associated macrophages have been shown to induce sub-lethal 
oxidative stress in murine mammary cancer cells, maybe through 
the secretion of TNF-α. On the other hand, extracellular super-
oxide dismutases might finely tuning the levels of H2O2 in the 
extracellular milieu altering the proliferation and differentia-
tion of immune cells (200). In fact, ROS may induce decreased 
viability in CD4+ T  lymphocytes and the inhibition of DNA 
synthesis (181, 201). The latter is associated with alterations in 
the TCR signaling, including conformational changes of TCRζ 
and LCK, reduction of PLCγ-1 phosphorylation and calcium 
flux, and increased ERK phosphorylation. Moreover, it has 
been known that prolonged exposure to H2O2 suppress tyrosine 
phosphorylation, calcium flux, NFAT, and NF-κB activation, and 
IL-2 production (191).
In vitro assays testing the resistance of different subsets 
T  lymphocytes to H2O2, it has been shown that it decreases 
from effector, to regulatory, naïve, and finally memory T  lym-
phocytes (201). Effector T  lymphocytes are able to withstand 
higher concentrations of ROS, which is probably essential to 
play their role in helping to phagocytes to eliminate pathogens 
(184). Whereas, human Tregs have higher thiol content and as 
a result, they are more resistant to cell death induced by H2O2 
secreted by granulocytes than conventional T lymphocytes (201). 
Tregs suppress GSH synthesis and cysteine release by DCs in a 
CTLA-4-dependent manner. The resulting decrease in intracel-
lular GSH leads to reduction in DNA synthesis in conventional 
T  lymphocytes (191, 202), reduced levels leads to membrane 
displacement of LAT (central adapter protein in the TCR), and 
responsiveness T lymphocytes. A recent study showed that Tregs 
modulate GSH metabolism in T lymphocytes via cell contact and 
antigen-dependent, but not by an antigen-specific mechanism 
during suppression (202). The mechanism has been not identi-
fied yet but it could involve NADPH oxidase. Macrophages have 
also been shown to suppress T lymphocyte activation in vitro and 
in  vivo through ROS (203) and, recent data demonstrates that 
macrophages induce Tregs via a ROS-dependent pathway that 
can be blocked by the NADPH oxidase inhibitor apocynin (204). 
In addition, scavenging enzymes that reduced oxidative intracel-
lular milieu influence the regulation of T  lymphocyte activity. 
Mitochondrial superoxide dismutase (MnSOD/SOD2) reduces 
T  lymphocyte differentiation and functional ability by decreas-
ing ROS levels (199, 205). Glutathione peroxidase-4 inhibits 
lipid peroxidation and plays a central role in the survival and the 
expansion of T lymphocytes.
In aging, the increase in oxidative stress and accumulated 
damage in the leukocytes appears to be related to the age-related 
deterioration of immune functions. A study by De la Fuente et al. 
reveals that the greater the cellular oxidative state and oxidative 
damage observed in immune cells of aged mice as well as in 
peripheral blood of elderly humans, were related with impaired 
immune responses (phagocytosis, chemotaxis, lymphoprolif-
eration, etc.). However, in healthy centenarian individuals and 
in very long-lived mice, with preserved immune functions, they 
all presented a decreased expression of different inflammatory 
genes and highly controlled oxidative stress in their immune 
cells, which can partly explain their longevity (206–209). It is 
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very important to emphasize in this context, that phagocytes, 
are postulated as the main responsible for oxidation-chronic 
inflammation stress that is associated with age and with immu-
nosenescence (210). In the end, as a result of the oxidative damage 
that is related to aging, these cells could lose the ability to regulate 
their redox and inflammatory state, with the result of producing 
more and more oxidizing and inflammatory compounds, and 
thus contribute to the increase of oxidative and inflammatory 
stress. On the other hand, there are several studies performed 
on macrophages and peripheral blood neutrophils, in mice and 
humans, which have shown that these cells produce higher levels 
of oxidized compounds than those produced by lymphocytes and 
these levels increase with age. Furthermore, all these oxidative 
and inflammatory disbalances have been related to functional 
dysfunction of T lymphocytes.
On the other hand, different sources of ROS are involved 
in the activation-induced cell death (AICD) expression of 
Fas ligand (FasL) of T  lymphocytes, and re-exposure to the 
specific antigen increases T  lymphocyte sensitivity. First, H2O2 
produced by DUOX-1 upon TCR serves to amplify proximal 
signaling events downstream of the TCR. Second, O 2•− released 
from mitochondrial Complex I, potentially in response to ERK 
signaling, triggers the expression of FasL. Finally, Fas ligation 
activates NOX-2, which probably contributes to the execution of 
the apoptotic program via H2O2-mediated activation of AKT and 
the inhibition of MEK. Moreover, cell-intrinsic antioxidants, such 
as glutathione, vitamin E, MnSOD, and CuZnSOD, interfere with 
FasL expression, thus counteracting AICD (184).
The selective cell death of effector cells with the memory 
phenotype may influence the size of the eventual memory 
T  lymphocyte pool and consequently the functional ability of 
the responding cells. More specifically, CTLs exhibiting an EM 
phenotype were preferentially sensitive to AICD, compared CTLs 
with a CM. This increased sensitivity of EM T  lymphocytes to 
TCR-induced AICD might correlate to the reduced levels of thiols 
in CD45RO+ T lymphocytes as compared to CD45RA+ memory 
T lymphocytes (211, 212). The loss of thiols after proliferation on 
repeated TCR stimulation may relate to apoptosis susceptibility. 
In this way, naïve T  lymphocytes have higher levels of surface 
thiols and higher production of intracellular GSH compared to 
the antigen-experienced T lymphocytes (213–215). In addition, 
scavengers could reduce ROS-induced apoptosis of naïve and 
memory T  lymphocytes. In fact, the increase levels of reduced 
thiol groups and intracellular GSH in a T  lymphocyte subset 
could be responsible for its increased ability to persist in an oxida-
tive stress microenvironment.
CONCLUSiON
Inflammation, both acute and chronic, both localized and sys-
temic, plays a key role in the differentiation and ontogeny of 
T lymphocytes. From the moment of formation in the bone mar-
row until arrival to exhausted or senescent status, inflammation 
influences the development of T  lymphocytes, and in turn the 
adaptive immune responses in the human body. The homeostasis 
and the way in which T lymphocytes respond to a specific antigen 
are influenced by the level of inflammation of the environment 
where the T lymphocytes are located. All the changes that occur 
along the ontogeny and differentiation of T lymphocytes require 
metabolic and oxidative adaptations. Despite the profound influ-
ence of inflammation in all these processes, little is known about 
the mechanisms through which it influences T  lymphocytes; 
therefore, this is a research field with great practical applications 
to explore.
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